Phase 3, multicenter, double-blind, parallel-group study to evaluate the efficacy and safety of TAK-085 in subjects with hypertriglyceridemia
Phase 3
- Conditions
- Hypertriglyceridemia
- Registration Number
- JPRN-jRCT2080220905
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Subjects diagnosed with hypertriglyceridemia, etc.
Exclusion Criteria
1. Subject had coronary artery disease
2. Subject received aortic aneurysmectomy
3. Subject had hemorrhagic disease etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method